# US 2024/0199577 A1 · Acoramidis analogs for stabilizing transthyretin and inhibiting transthyretin misfolding

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199577 A1
- Document ID: US20240199577A1
- Status: Published application
- Kind: A1
- Application number: 18/419,303
- Filed: 2024-01-22
- Published: 2024-06-20
- Earliest claimed: 2021-07-28
- Assignees: Protego Biopharma, Inc.
- Applicants: Protego Biopharma, Inc.
- Inventors: Richard F. Labaudiniere; Bradley Dean Tait
- Web page: https://patentgrep.com/patent/US20240199577A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/04: for urolithiasis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds having activity against TTR related conditions, and pharmaceutically accepted salts and solvates thereof. Also provided are methods of using the compounds for inhibiting and preventing TTR aggregation and/or amyloid formation in the peripheral nerves, kidney, cardiac tissue, eye and CNS, and of treating a subject with peripheral TTR amyloidosis.

## Claims

### Claim 1

A compound having the structure of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
A is
X1 is O, S or NR6;
X2 is a bond, O, S, NR6, N+R6R7 or P+(Ar)2;
X3 is O, S or NR6;
n is an integer from 0-6;
m is an integer from 0-6;
Ar is aryl, heteroaryl or heteroarylium, all optionally substituted;
R1, R2, R3, R4, R5, R6 and R7 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted, or OH, OR8, COR9, —(CR10R11)mX3R8 or —(CR10R11)mX3COR9;
R8 and R9 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted;
or R8 is selected as above and R9 is
R10 and R11 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted, or OH or OR8;
or R1-R2 form a cycloalkyl or heterocycloalkyl; and R3-R11 are selected as above;
or R3-R4 form a cycloalkyl or heterocycloalkyl; and R1, R2 and R5-R11 are selected as above;
or R10-R11 form a cycloalkyl or heterocycloalkyl; and R1-R9 are selected as above;
or R1-R3 form a bond, —(CR10R11)m— or —(CR10═CR11)m—; and R2 and R4-R11 are selected as above;
or R2-R4 form a bond, —(CR10R11)m— or —(CR10═CR11)m—; and R1, R3 and R5-R11 are selected as above;
or R1-R5 form a bond, —(CR10R11)m— or —(CR10═CR11)m—; and R2 -R4 and R6-R11 are selected as above;
or R2-R6 form a bond, —(CR10R11)m— or —(CR10═CR11)m—; and R1, R3-R5 and R7-R11 are selected as above;
or R3-R5 form a bond, —(CR10R11)m—, —(CR10═CR11)m— or —[C(R10)═C(R11)—CO]—; and R1, R2, R4 and R6-R11 are selected as above;
or R4-R6 form a bond, —(CR10R11)m— or —(CR10═CR11)m—; and R1-R3, R5 and R7-R11 are selected as above;
or R5-R6 form —(CR10R11)m— or —(CR10R11)m—X3—(CR10R11)m—; and R1-R4 and R7-R11 are selected as above;
with the provisos that:
when X1 is oxygen, X2 is a bond, and R1, R2 and R5 are H, then n is not 0; and
when X1 is NH, X2 is a bond, and R1, R2, R3, R4 and R5 are H, then n is not 1.

### Claim 2

A compound having the structure of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
A is
X1 O, S or NR6;
X2 is a bond, O, S, NR6, N+R6R7 or P+(Ar)2;
X3 is O, S or NR6;
n is an integer from 0-6;
m is an integer from 0-6;
Ar is aryl, heteroaryl or heteroarylium, all optionally substituted;
R1, R2, R3, R4, R5, R6 and R7 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted, or OH, OR8, COR9, —(CR10R11)mX3R8 or —(CR10R11)mX3COR9;
R8 and R9 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted;
or R8 is selected as above and R9 is
R10 and R11 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted, or OH or OR8;
or R1-R2 form a cycloalkyl or heterocycloalkyl; and R3-R11 are selected as above;
or R3-R4 form a cycloalkyl or heterocycloalkyl; and R1, R2 and R5-R11 are selected as above;
or R10-R11 form a cycloalkyl or heterocycloalkyl; and R1-R9 are selected as above;
or R1-R3 form a bond, —(CR10R11)m— or —(CR10═CR11)m—; and R2 and R4-R11 are selected as above;
or R2-R4 form a bond, —(CR10R11)m— or —(CR10═CR11)m—; and R1, R3 and R5-R11 are selected as above;
or R1-R5 form a bond, —(CR10R11)m— or —(CR10═CR11)m—; and R2-R4 and R6-R11 are selected as above;
or R2-R6 form a bond, —(CR10R11)m— or —(CR10═CR11)m—; and R1, R3-R5 and R7-R11 are selected as above;
or R3-R5 form a bond, —(CR10R11)m—, —(CR10═CR11)m— or —[C(R10)═C(R11)—CO]—; and R1, R2, R4 and R6-R11 are selected as above;
or R4-R6 form a bond, —(CR10R11)m— or —(CR10═CR11)m—; and R1-R3, R5 and R7-R11 are selected as above;
or R5-R6 form —(CR10R11)m— or —(CR10R11)m—X3—(CR10R11)m—; and R1-R4 and R7-R11 are selected as above.

### Claim 3

The compound having one of the following structures:

### Claim 4 (depends on 1, 2, 3)

A pharmaceutical composition, comprising the compound of claim 1, 2 or 3, and a pharmaceutically acceptable excipent.

### Claim 5 (depends on 1, 2, 3)

A method of inhibiting and preventing TTR aggregation and/or amyloid formation in the eye or CNS of a subject, comprising administering to the subject the compound of claim 1, 2 or 3.

### Claim 6 (depends on 1, 2, 3)

A method of treating a subject having peripheral TTR amyloidosis or ocular or cerebral amyloid angiopathy, comprising administering to the subject the compound of claim 1, 2 or 3.

### Claim 7 (depends on 1, 2, 3)

A method of treating a subject having familial amyloid polyneuropathy, familial amyloid cardiomyopathy, localized nodular cutaneous amyloidosis, TTR oculoleptomeningeal amyloidosis or senile systemic amyloidosis, comprising administering to the subject the compound of claim 1, 2 or 3.
